What is the project about?
EMPIRE study is a randomised, double-blind, placebo-controlled trial: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377432&isReview=true. The purpose of EMPIRE study is to determine the combined effects of HMB and Vitamin D vs vitamin D alone (placebo) on musculoskeletal health in older patients with osteoporosis and sarcopenia.
Gait speed is the primary outcome; secondary outcomes include CT-measured bone density and muscle volume and falls incidence.
What are the expected outcomes?
We hypothesize that patients on HMB+Vitamin D will improve both bone density and muscle mass/function vs placebo. HMB, an anabolic amino acid, is a positive regulator of muscle and bone metabolism and may interact with vitamin D to superimpose the effects on musculoskeletal health. Outcomes may have an impact on health policy guidelines and clinical practice.
The Global Leadership Initiative in Sarcopenia (GLIS):
We developed the first global definition of sarcopenia for research and clinical practice. Paper attached. This definition was included in the International Classifications of Diseases ICD-11.
